The clinical nurse specialist was also diagnosed with stage III invasive lobular breast cancer and was treated with CDK 4/6 inhibitors, giving her the unique opportunity to speak to both the patient and clinical perspective.
The geriatric oncologist spoke about the differences in treating older women and younger women with triple-negative breast cancer.
The breast medical oncologist discussed new treatment options for triple negative breast cancer as new targets become readily available for this aggressive cancer type.
The breast oncologist from the University of California, San Francisco, discussed new agents being developed in the breast cancer space.
The breast cancer expert spoke about decreasing the amount of treatment to receive the same impact for patients with breast cancer.
After a serious adverse reaction to a clinical trial put her in critical condition, Barbara Bigelow now shows no signs of breast cancer and is no longer on any cancer medications.
At the 37th Annual Miami Breast Cancer Conference, Valerie Lemaine, MD, MPH, FRCSC, told physicians what they need should know and discuss with their patients about BIA-ALCL.
Scott Gottlieb, MD, spoke about the spread of the novel coronavirus (COVID-19) during the keynote address at the 37th Annual Miami Breast Cancer Conference®.
The goal of the study is to determine the effect of adagloxad simolenin administered with the potent adjuvant OBI-821 as a therapeutic vaccine treatment on improving invasive disease-free survival in the study population.
Aditya Bardia, MD, MPH detailed the clinical development of antibody drug conjugates in patients with metastatic triple negative breast cancer, as well as what to expect moving forward with antibody drug conjugates in the metastatic breast cancer space.